Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Int J Mol Sci ; 25(3)2024 Jan 24.
Article in English | MEDLINE | ID: mdl-38338694

ABSTRACT

The arbovirus Chikungunya (CHIKV) is transmitted by Aedes mosquitoes in urban environments, and in humans, it triggers debilitating symptoms involving long-term complications, including arthritis and Guillain-Barré syndrome. The development of antiviral therapies is relevant, as no efficacious vaccine or drug has yet been approved for clinical application. As a detailed map of molecules underlying the viral infection can be obtained from the metabolome, we validated the metabolic signatures of Vero E6 cells prior to infection (CC), following CHIKV infection (CV) and also upon the inclusion of the nsP2 protease inhibitor wedelolactone (CWV), a coumestan which inhibits viral replication processes. The metabolome groups evidenced significant changes in the levels of lactate, myo-inositol, phosphocholine, glucose, betaine and a few specific amino acids. This study forms a preliminary basis for identifying metabolites through HR-MAS NMR (High Resolution Magic Angle Spinning Nuclear Magnetic Ressonance Spectroscopy) and proposing the affected metabolic pathways of cells following viral infection and upon incorporation of putative antiviral molecules.


Subject(s)
Aedes , Chikungunya Fever , Animals , Chlorocebus aethiops , Humans , Vero Cells , Metabolomics , Virus Replication , Antiviral Agents/pharmacology
2.
PLoS Negl Trop Dis ; 17(11): e0011710, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37943879

ABSTRACT

BACKGROUND: The co-circulation of flaviviruses in tropical regions has led to the hypothesis that immunity generated by a previous dengue infection could promote severe disease outcomes in subsequent infections by heterologous serotypes. This study investigated the influence of antibodies generated by previous Zika infection on the clinical outcomes of dengue infection. METHODOLOGY/PRINCIPAL FINDINGS: We enrolled 1,043 laboratory confirmed dengue patients and investigated their prior infection to Zika or dengue. Severe forms of dengue disease were more frequent in patients with previous Zika infection, but not in those previously exposed to dengue. CONCLUSIONS/SIGNIFICANCE: Our findings suggest that previous Zika infection may represent a risk factor for subsequent severe dengue disease, but we did not find evidence of antibody-dependent enhancement (higher viral titer or pro-inflammatory cytokine overexpression) contributing to exacerbation of the subsequent dengue infection.


Subject(s)
Dengue Virus , Dengue , Zika Virus Infection , Zika Virus , Humans , Antibodies, Viral , Cross Reactions
3.
Microorganisms ; 10(7)2022 Jun 30.
Article in English | MEDLINE | ID: mdl-35889050

ABSTRACT

Several neurotropic viruses are members of the flavivirus and alphavirus families. Infections caused by these viruses may cause long-term neurological sequelae in humans. The continuous emergence of infections caused by viruses around the world, such as the chikungunya virus (CHIKV) (Alphavirus genus), the zika virus (ZIKV) and the yellow fever virus (YFV) (both of the Flavivirus genus), warrants the development of new strategies to combat them. Our study demonstrates the inhibitory potential of the water-soluble vitamin riboflavin against NS2B/NS3pro of ZIKV and YFV and nsP2pro of CHIKV. Riboflavin presents a competitive inhibition mode with IC50 values in the medium µM range of 79.4 ± 5.0 µM for ZIKV NS2B/NS3pro and 45.7 ± 2.9 µM for YFV NS2B/NS3pro. Against CHIKV nsP2pro, the vitamin showed a very strong effect (93 ± 5.7 nM). The determined dissociation constants (KD) are significantly below the threshold value of 30 µM. The ligand binding increases the thermal stability between 4 °C and 8 °C. Unexpectedly, riboflavin showed inhibiting activity against another viral protein; the molecule was also able to inhibit the viral entry of CHIKV. Molecular dynamics simulations indicated great stability of riboflavin in the protease active site, which validates the repurposing of riboflavin as a promising molecule in drug development against the viruses presented here.

4.
Virus Res ; 307: 198610, 2022 01 02.
Article in English | MEDLINE | ID: mdl-34718046

ABSTRACT

Arboviruses are transmitted by arthropods (arthropod-borne virus) which can be mosquitoes or other hematophagous arthropods, in which their life cycle occurs before transmission to other hosts. Arboviruses such as Dengue, Zika, Saint Louis Encephalitis, West Nile, Yellow Fever, Japanese Encephalitis, Rocio and Murray Valley Encephalitis viruses are some of the arboviruses transmitted biologically among vertebrate hosts by blood-taking vectors, mainly Aedes and Culex sp., and are associated with neurological, viscerotropic, and hemorrhagic reemerging diseases, posing as significant health and socioeconomic concern, as they become more and more adaptive to new environments, to arthropods vectors and human hosts. One of the main families that include mosquito-borne viruses is Flaviviridae, and here, we review the case of the Flavivirus genus, which comprises the viruses cited above, using a variety of research approaches published in literature, including genomics, transcriptomics, proteomics, metabolomics, etc., to better understand their structures as well as virus-host interactions, which are essential for development of future antiviral therapies.


Subject(s)
Aedes , Arboviruses , Flavivirus , Zika Virus Infection , Zika Virus , Animals , Arboviruses/genetics , Flavivirus/genetics , Humans , Mosquito Vectors
5.
J Med Virol ; 94(2): 776-781, 2022 02.
Article in English | MEDLINE | ID: mdl-34664719

ABSTRACT

We describe the circulation of Saint Louis encephalitis virus (SLEV) in two Brazilian States during outbreaks of Dengue and Zika viruses. We detected the virus in a patient from Araraquara, State of São Paulo, and in patients and in a mosquito pool of Culex quinquefasciatus from Sinop, State of Mato Grosso. Phylogenetic analysis grouped samples from this study within genotype V, which are closely related to other strains that previously circulated in other parts of the country. Genotype V seems to have established circulation in Brazil.


Subject(s)
Culicidae/virology , Encephalitis Virus, St. Louis/genetics , Encephalitis, St. Louis/virology , Genotype , Adolescent , Animals , Brazil/epidemiology , Child , Child, Preschool , Dengue/epidemiology , Disease Outbreaks , Encephalitis Virus, St. Louis/isolation & purification , Female , Humans , Infant , Male , Phylogeny , Zika Virus Infection/epidemiology
6.
PLoS One ; 16(3): e0246319, 2021.
Article in English | MEDLINE | ID: mdl-33661906

ABSTRACT

The potential outcome of flavivirus and alphavirus co-infections is worrisome due to the development of severe diseases. Hundreds of millions of people worldwide live under the risk of infections caused by viruses like chikungunya virus (CHIKV, genus Alphavirus), dengue virus (DENV, genus Flavivirus), and zika virus (ZIKV, genus Flavivirus). So far, neither any drug exists against the infection by a single virus, nor against co-infection. The results described in our study demonstrate the inhibitory potential of two flavonoids derived from citrus plants: Hesperetin (HST) against NS2B/NS3pro of ZIKV and nsP2pro of CHIKV and, Hesperidin (HSD) against nsP2pro of CHIKV. The flavonoids are noncompetitive inhibitors and the determined IC50 values are in low µM range for HST against ZIKV NS2B/NS3pro (12.6 ± 1.3 µM) and against CHIKV nsP2pro (2.5 ± 0.4 µM). The IC50 for HSD against CHIKV nsP2pro was 7.1 ± 1.1 µM. The calculated ligand efficiencies for HST were > 0.3, which reflect its potential to be used as a lead compound. Docking and molecular dynamics simulations display the effect of HST and HSD on the protease 3D models of CHIKV and ZIKV. Conformational changes after ligand binding and their effect on the substrate-binding pocket of the proteases were investigated. Additionally, MTT assays demonstrated a very low cytotoxicity of both the molecules. Based on our results, we assume that HST comprise a chemical structure that serves as a starting point molecule to develop a potent inhibitor to combat CHIKV and ZIKV co-infections by inhibiting the virus proteases.


Subject(s)
Chikungunya virus/enzymology , Citrus/chemistry , Hesperidin/pharmacology , Peptide Hydrolases/metabolism , Zika Virus/enzymology , Animals , Chikungunya virus/drug effects , Chlorocebus aethiops , Humans , Inhibitory Concentration 50 , Models, Molecular , Molecular Docking Simulation , Peptide Hydrolases/chemistry , Plant Extracts/chemistry , Protein Conformation , Vero Cells , Viral Proteins/chemistry , Viral Proteins/metabolism , Zika Virus/drug effects
7.
J Proteome Res ; 16(4): 1542-1555, 2017 04 07.
Article in English | MEDLINE | ID: mdl-28317380

ABSTRACT

Yellow fever virus (YFV) replication is highly dependent on host cell factors. YFV NS4B is reported to be involved in viral replication and immune evasion. Here interactions between NS4B and human proteins were determined using a GST pull-down assay and analyzed using 1-DE and LC-MS/MS. We present a total of 207 proteins confirmed using Scaffold 3 Software. Cyclophilin A (CypA), a protein that has been shown to be necessary for the positive regulation of flavivirus replication, was identified as a possible NS4B partner. 59 proteins were found to be significantly increased when compared with a negative control, and CypA exhibited the greatest difference, with a 22-fold change. Fisher's exact test was significant for 58 proteins, and the p value of CypA was the most significant (0.000000019). The Ingenuity Systems software identified 16 pathways, and this analysis indicated sirolimus, an mTOR pathway inhibitor, as a potential inhibitor of CypA. Immunofluorescence and viral plaque assays showed a significant reduction in YFV replication using sirolimus and cyclosporine A (CsA) as inhibitors. Furthermore, YFV replication was strongly inhibited in cells treated with both inhibitors using reporter BHK-21-rep-YFV17D-LucNeoIres cells. Taken together, these data suggest that CypA-NS4B interaction regulates YFV replication. Finally, we present the first evidence that YFV inhibition may depend on NS4B-CypA interaction.


Subject(s)
Cyclophilin A/metabolism , Proteins/genetics , Virus Replication/genetics , Yellow fever virus/genetics , Cyclophilin A/genetics , Host-Pathogen Interactions/drug effects , Humans , Signal Transduction/drug effects , Sirolimus/administration & dosage , Systems Biology , TOR Serine-Threonine Kinases/antagonists & inhibitors , Viral Nonstructural Proteins/metabolism , Virus Replication/drug effects , Yellow fever virus/pathogenicity
8.
Immunology ; 145(4): 583-96, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25939314

ABSTRACT

Dengue is a mosquito-borne disease that affects millions of people worldwide yearly. Currently, there is no vaccine or specific treatment available. Further investigation on dengue pathogenesis is required to better understand the disease and to identify potential therapeutic targets. The chemokine system has been implicated in dengue pathogenesis, although the specific role of chemokines and their receptors remains elusive. Here we describe the role of the CC-chemokine receptor CCR5 in Dengue virus (DENV-2) infection. In vitro experiments showed that CCR5 is a host factor required for DENV-2 replication in human and mouse macrophages. DENV-2 infection induces the expression of CCR5 ligands. Incubation with an antagonist prevents CCR5 activation and reduces DENV-2 positive-stranded (+) RNA inside macrophages. Using an immunocompetent mouse model of DENV-2 infection we found that CCR5(-/-) mice were resistant to lethal infection, presenting at least 100-fold reduction of viral load in target organs and significant reduction in disease severity. This phenotype was reproduced in wild-type mice treated with CCR5-blocking compounds. Therefore, CCR5 is a host factor required for DENV-2 replication and disease development. Targeting CCR5 might represent a therapeutic strategy for dengue fever. These data bring new insights on the association between viral infections and the chemokine receptor CCR5.


Subject(s)
Dengue Virus/physiology , Dengue/immunology , Macrophages/immunology , Receptors, CCR5/immunology , Virus Replication/immunology , Animals , Base Sequence , Dengue/drug therapy , Dengue/genetics , Humans , Macrophages/pathology , Macrophages/virology , Mice , Mice, Knockout , Molecular Sequence Data , Receptors, CCR5/genetics , Virus Replication/drug effects , Virus Replication/genetics
9.
Antiviral Res ; 111: 82-92, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25241249

ABSTRACT

Exploiting the inhibition of host signaling pathways aiming for discovery of potential antiflaviviral compounds is clearly a beneficial strategy for the control of life-threatening diseases caused by flaviviruses. Here we describe the antiviral activity of the MEK1/2 inhibitor U0126 against Yellow fever virus 17D vaccine strain (YFV-17D). Infection of VERO cells with YFV-17D stimulates ERK1/2 phosphorylation early during infection. Pharmacological inhibition of MEK1/2 through U0126 treatment of VERO cells blockades not only the YFV-stimulated ERK1/2 phosphorylation, but also inhibits YFV replication by ∼99%. U0126 was also effective against dengue virus (DENV-2 and -3) and Saint-Louis encephalitis virus (SLEV). Levels of NS4AB, as detected by immunofluorescence, are diminished upon treatment with the inhibitor, as well as the characteristic endoplasmic reticulum membrane invagination stimulated during the infection. Though not protective, treatment of YFV-infected, adult BALB/c mice with U0126 resulted in significant reduction of virus titers in brains. Collectively, our data suggest the potential targeting of the MEK1/2 kinase as a therapeutic tool against diseases caused by flaviviruses such as yellow fever, adverse events associated with yellow fever vaccination and dengue.


Subject(s)
Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Virus Replication , Yellow Fever/enzymology , Yellow fever virus/physiology , Animals , Chlorocebus aethiops , Enzyme Activation , Host-Pathogen Interactions , Humans , Male , Mice , Mice, Inbred BALB C , Mitogen-Activated Protein Kinase 1/genetics , Mitogen-Activated Protein Kinase 3/genetics , Vero Cells , Yellow Fever/genetics , Yellow Fever/virology , Yellow fever virus/genetics
10.
Arch Virol ; 156(6): 931-8, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21298455

ABSTRACT

The flavivirus NS5 protein is one of the most important proteins of the replication complex, and cellular proteins can interact with it. This study shows for the first time that the yellow fever virus (YFV) NS5 protein is able to interact with U1A, a protein involved in splicing and polyadenylation. We confirmed this interaction by GST-pulldown assay and by co-immunoprecipitation in YFV-infected cells. A region between amino acids 368 and 448 was identified as the site of interaction of the NS5 protein with U1A. This region was conserved among some flaviviruses of medical importance. The implications of this interaction for flavivirus replication are discussed.


Subject(s)
Protein Interaction Domains and Motifs , Ribonucleoprotein, U1 Small Nuclear/metabolism , Viral Nonstructural Proteins/metabolism , Yellow fever virus , Amino Acid Sequence , Animals , Binding Sites , Chlorocebus aethiops , Conserved Sequence , HeLa Cells , Humans , Immunoprecipitation , Polymerase Chain Reaction , Protein Binding , RNA, Viral , Ribonucleoprotein, U1 Small Nuclear/chemistry , Two-Hybrid System Techniques , Vero Cells , Viral Nonstructural Proteins/chemistry , Yellow fever virus/genetics , Yellow fever virus/metabolism
11.
Virus Genes ; 38(2): 224-31, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19169857

ABSTRACT

RNA interference (RNAi) is a process that is induced by double stranded RNA and involves the degradation of specific sequences of mRNA in the cytoplasm of the eukaryotic cells. It has been used as an antiviral tool against many viruses, including flaviviruses. The genus Flavivirus contains the most important arboviruses in the world, i.e., dengue (DENV) and yellow fever (YFV). In our study, we investigated the in vitro and in vivo effect of RNAi against YFV. Using stable cell lines that expressed RNAi against YFV, the cell lines were able to inhibit as much as 97% of the viral replication. Two constructions (one against NS1 and the other against E region of YFV genome) were able to protect the adult Balb/c mice against YFV challenge. The histopathologic analysis demonstrated an important protection of the central nervous system by RNAi after 10 days of viral challenge. Our data suggests that RNAi is a potential viable therapeutic weapon against yellow fever.


Subject(s)
Antiviral Agents/therapeutic use , RNA Interference , RNA, Small Interfering/therapeutic use , Virus Replication , Yellow Fever/drug therapy , Yellow fever virus/drug effects , Yellow fever virus/physiology , Animals , Antiviral Agents/pharmacology , Central Nervous System/pathology , Chlorocebus aethiops , Mice , Mice, Inbred BALB C , RNA, Small Interfering/pharmacology , Survival Analysis , Vero Cells , Viral Envelope Proteins/antagonists & inhibitors , Viral Envelope Proteins/genetics , Viral Nonstructural Proteins/antagonists & inhibitors , Viral Nonstructural Proteins/genetics , Yellow Fever/pathology , Yellow fever virus/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...